Nkarta, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Mar 2026

NKTX

10-K: Nkarta Shifts Focus to Autoimmune, Reports Reduced Losses

Nkarta, Inc. reports a strategic pivot to autoimmune disease therapies with its lead candidate NKX019, alongside reduced net losses and a strong cash position for the next 12 months.

NASDAQ

26 Mar 2025

NKTX

Nkarta, INC

10-K: Nkarta's 2024 10-K Filing: Prioritizing Autoimmune Therapies Amidst Financial Realignment

Nkarta's 2024 10-K filing highlights a strategic shift towards autoimmune disease therapies, particularly NKX019, while managing financial resources through cost-containment measures and capital raising.

NASDAQ

21 Mar 2024

NKTX

Nkarta, INC

10-K: Nkarta, Inc. Outlines Capital Stock and Business Strategy in 10-K Filing

Nkarta, Inc.'s 10-K filing details the company's capital structure, ongoing clinical trials, and strategic focus on developing allogeneic NK cell therapies for autoimmune diseases and cancer.